| 1CVW | H: | CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA) |
| 1DAN | H: | COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR |
| 1DVA | H:; I: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA |
| 1FAK | H: | HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT |
| 1J9C | H: | CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX |
| 1JBU | H: | COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183 |
| 1KLI | H: | COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA |
| 1KLJ | H: | CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA |
| 1O5D | H: | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
| 1QFK | H: | STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION |
| 1YGC | H: | SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR |
| 1Z6J | H: | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR |
| 2A2Q | H: | COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+ |
| 2AEI | H: | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID |
| 2B7D | H: | FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL |
| 2B8O | H: | CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX |
| 2C4F | H:16-257 | CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121 |
| 2F9B | H: | DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS |
| 2FIR | H: | CRYSTAL STRUCTURE OF DFPR-VIIA/STF |
| 2FLB | H: | DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR |
| 2FLR | H: | NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS |
| 2PUQ | H: | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
| 2ZP0 | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE |
| 2ZWL | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR |
| 2ZZU | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE |
| 3ELA | H: | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
| 3TH2 | H: | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
| 3TH3 | H: | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
| 3TH4 | H: | MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+ |
| 4ISH | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR BMS-593214 ALSO KNOWN AS 2'-[(6R,6AR,11BR)-2-CARBAMIMIDOYL-6,6A,7,11B-TETRAHYDRO-5H-INDENO[2,1-C]QUINOLIN-6-YL]-5'-HYDROXY-4'-METHOXYBIPHENYL-4-CARBOXYLIC ACID |
| 4ISI | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (6S)-N-(4-CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-8,8-DIETHYL-4-OXO-4,6,7,8-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE |
| 4JYU | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(PHENYLSULFONYL)ETHANAMIDE |
| 4JYV | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-2-(ISOQUINOLIN-6-YLAMINO)-N-[(3-SULFAMOYLPHENYL)SULFONYL]ETHANAMIDE |
| 4JZD | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(4-CARBAMIMIDOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID |
| 4JZE | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(1-AMINOISOQUINOLIN-6-YL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID |
| 4JZF | H: | STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(3-CARBAMOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY-3,3-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID |
| 4NA9 | H: | FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 3'-AMINO-5'-[(2S,4R)-6-CARBAMIMIDOYL-4-PHENYL-1,2,3,4-TETRAHYDROQUINOLIN-2-YL]BIPHENYL-2-CARBOXYLIC ACID |
| 4NG9 | H: | FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(3-SULFAMOYLBENZYL)ETHANAMIDE |
| 4NGA | H: | FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-[2-(PROPAN-2-YLSULFONYL)BENZYL]ETHANAMIDE |
)
)